Erudio Healtherudio.com
Drug
Telisotuzumab adizutecan trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying telisotuzumab adizutecan: M21-404. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 3 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| M21-404 NCT05029882 · AbbVie | advanced solid tumors | Phase 1 | 152 | 62 | Standard | Nov 2, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| AndroMETa-CRC NCT07525206 · AbbVie FocusedView → | refractory metastatic colorectal cancer | Phase 3 | Focused | View | |||
| AndroMETa-CRC-064 NCT06614192 · AbbVie FocusedView → | refractory metastatic colorectal cancer expressing c-Met protein | Phase 2 | Focused | View | |||
| NCT06084481 NCT06084481 · AbbVie FocusedView → | Not given | Phase 1 | Focused | View | |||